Heart failure: an analysis of the management of decompensated patients in the emergency room

Authors

  • Thatiana Simão de Oliveira Centro Universitário Presidente Antônio Carlos - Juiz de Fora Author
  • Isabella Gonçalves Bertolin Centro Universitário Presidente Antônio Carlos - Juiz de Fora Author
  • Thatiely Castro Paulino Universidad Privada Del Leste Author
  • Thaynata Castro Paulino de Carvalho Universidad Privada del Este Author
  • Ivan José de Almeida Neto Centro Universitário Presidente Tancredo de Almeida Neves - São João del Rei Author
  • Marcos Martinelle Dionizio Almeida Centro Universitário Presidente Antônio Carlos - Juiz de Fora Author
  • Ariane Dias dos Santos Afya Abaetetuba Author
  • Thales Corrêa de Oliveira Centro Universitário Presidente Tancredo de Almeida Neves - São João Del Rei Author
  • Isabella Lyandra Malato Lima da Silva Centro Universitário FIBRA Author
  • Juliana Guerra dos Reis Cavalcanti de Albuquerque Afya - Faculdade de Ciências Médicas de Jaboatão Author

DOI:

https://doi.org/10.5281/zenodo.13622858

Keywords:

Cardiology, Heart failure, Management

Abstract

Heart failure (HF) is a complex clinical condition characterized by the inability of the heart to maintain adequate blood flow to satisfy the metabolic needs of tissues or to maintain central venous pressure at normal levels, without excessive volumetric overload. The treatment of heart failure (HF) in the emergency room setting is a critical and intensive approach that aims to immediately stabilize the patient, alleviate acute symptoms, and correct hemodynamic and metabolic imbalances. This systematic review analyzed articles on emergency heart failure management published in the last 5 years. The databases PubMed, LILACS, Periódicos CAPES, EMBASE and Scielo were searched, using the descriptors “Heart failure” and “Emergency room”. Studies on humans or animals in Portuguese, English and Spanish were included. After filtering duplicates and irrelevant articles, 5 studies were selected for analysis. Thus, study findings suggest that intensive therapeutic strategies, early use of empagliflozin and dapagliflozin, and implementation of structured decision support approaches can significantly improve clinical outcomes in patients with AHF. However, there is a need for more research to deepen the understanding of interactions between different therapies, over the long term and in diverse populations, to further optimize management strategies and maximize benefits for patients. Additional studies are needed to validate the effectiveness of these treatments in different clinical scenarios and evaluate their implications for long-term management practices.

References

BORLAUG, B. A. Evaluation and management of heart failure with preserved ejection fraction. Nature Reviews Cardiology, v. 17, n. 9, p. 559–573, 30 mar. 2020.

CASTIGLIONE, V. et al. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, v. 27, n. 2, p. 625–643, 14 abr. 2021.

COSTANZO, M. R. The Cardiorenal Syndrome in Heart Failure. Heart Failure Clinics, v. 16, n. 1, p. 81–97, 1 jan. 2020.

COX, Z. L. et al. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. Journal of the American College of Cardiology, v. 83, n. 14, p. 1295–1306, 1 abr. 2024.

FERREIRA, J. P. et al. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE. European Journal of Heart Failure, v. 25, n. 10, p. 1797–1805, 22 ago. 2023.

GTIF, I. et al. Heart failure disease: An African perspective. Archives of cardiovascular diseases, v. 114, n. 10, p. 680–690, 1 out. 2021.

LEE, D. S. et al. Trial of an Intervention to Improve Acute Heart Failure Outcomes. New England Journal of Medicine, v. 388, n. 1, p. 22–32, 5 jan. 2023.

LOGSTRUP, B. B.. Heart Failure in Rheumatic Disease. Rheumatic Disease Clinics of North America, v. 49, n. 1, p. 67–79, 1 fev. 2023.

MCDONAGH, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Revista Española de Cardiología (English Edition), v. 75, n. 6, p. 523–523, 1 jun. 2022.

MEBAZAA, A. et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet, v. 400, n. 10367, p. 1938–1952, 1 dez. 2022.

TOMASONI, D. et al. Highlights in heart failure. ESC Heart Failure, v. 6, n. 6, p. 1105–1127, 1 dez. 2019.

VOORS, A. A. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, v. 28, n. 3, p. 568–574, 28 fev. 2022.

WILCOX, J. E. et al. Heart Failure With Recovered Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, v. 76, n. 6, p. 719–734, 1 ago. 2020.

Published

2024-08-31

Issue

Section

Articles

How to Cite

OLIVEIRA, Thatiana Simão de et al. Heart failure: an analysis of the management of decompensated patients in the emergency room. Journal of Social Issues and Health Sciences (JSIHS), [S. l.], v. 1, n. 5, 2024. DOI: 10.5281/zenodo.13622858. Disponível em: https://ojs.thesiseditora.com.br/index.php/jsihs/article/view/140.. Acesso em: 4 feb. 2026.